乳腺癌寡转移系统治疗联合SBRT的困惑和前景  

Confusion and prospect of systemic therapy combined with SBRT in oligometastatic breast cancer

作　　者：陈楚莹 郑思悦 曹璐[1] 陈佳艺[1] CHEN Chuying;ZHENG Siyue;CAO Lu;CHEN Jiayi(Department of Radiation Oncology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院放射治疗科,上海200025

出　　处：《中国癌症杂志》2020年第11期905-911,共7页China Oncology

基　　金：国家自然科学基金(81673102,81602791,81803164,81972963);国家重点研发计划(2016YFC0105409);上海市科学技术委员会“科技创新行动计划”(19411950902)。

摘　　要：转移性乳腺癌(metastatic breast cancer,MBC)被认为不可治愈,患者生存预后不佳。但在MBC中存在一部分人群,转移灶的数目和大小较局限,有潜在治愈可能,即寡转移乳腺癌(oligometastatic breast cancer,OMBC)。立体定向放射治疗(stereotactic body radiation therapy,SBRT)联合系统治疗有望延缓OMBC患者的疾病进展,改善生存。如何寻找真正的OMBC患者,SBRT是否覆盖所有转移病灶,联用何种系统治疗方式,都是当下值得探讨的问题。Metastatic breast cancer(MBC)is considered incurable with poor outcome.There is a subset of patients with oligometastatic breast cancer(OMBC)having limited metastases in number and size which can be potentially cured.The disease progression is expected to be delayed with survival improvement in the subgroup when patients are treated with stereotactic body radiation therapy(SBRT)combined with systemic therapy.Problems currently deserved to be discussed include how to find the true OMBC,which metastases to be targeted and what kind of systemic therapy to be combined with.

关 键 词：寡转移乳腺癌 立体定向放射治疗 系统治疗 

分 类 号：R737.9[医药卫生—肿瘤]